MedTrace Logo

Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation

NCT01729676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2014-07-17

No results posted yet for this study

Summary

French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).

Conditions

Interventions

DRUG

Degarelix or GnRH agonist

Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01729676 on ClinicalTrials.gov